Research programme: GPCR modulators - Merck/Nxera Pharma
Latest Information Update: 02 Apr 2024
Price :
$50 *
At a glance
- Originator Heptares Therapeutics
- Developer Cubist Pharmaceuticals; Nxera Pharma
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified